| Mechanism | Drug (Generic) | Clinical Uses |
| fusion protein of human IgG constant regions fused to TNF receptor, binds to TNFα and TNFβ; blocks TNF from binding receptor, leading to suppression of inflammatory cytokines and | |
| metabolized into a fraudulent nucleotide, causing chain termination | |
| chimeric human-mouse AB that recognizes TNFα; blocks TNFα from binding receptor, leading to suppression of inflammatory cytokines (IL-1, IL-6) and adhesion molecules | |
| binds to FKBP, inhibititing calcineurin required for dephosphorylation of NF-ATc, thus inhibiting T-cell activation | |
| binds Rho antigens, prevents sensitization of Rh-negative women to an Rh-positive fetus | |
| inhibits purine synthesis | |
| chimeric human-mouse Ab that recognizes CD20 (pan B-cell prot) | |
| alkylating agent; transfers alkyl group to protein, DNA, RNA, etc | |
| Human monoclonal antibody that recognizes cytokine B Lymphocyte stimulator (BLYS) | |
| humanized Ab that recognizes CD52 present on T- and B-cells; binds to CD52 on normal and malignant T- and B-cells, killing them by Ab-dependant lysis | |
| | Mechanism | Drug (Generic) | Clinical Uses |
| human Ab that recognizes TNFα; blocks TNFα from binding receptor, leading to suppression of inflammatory cytokines and adhesion molecules | |
| interferes with cell cycle of activated lymphoid cells, inhibits produciton of inflammatory mediators | |
| recognizes human CD3 molecule on T-cells, inactivating T-cell function | |
| folic acid antagonist that inhibits dihydrofolate reductase, thus inhibiting DNA, RNA, and protein synthesis | |
| binds to FKBP-12, inhibiting activity of mTOR (does NOT affect calcineurin activity), thus inhibiting cell cycle progression from G1 to S phase | |
| fusion protein of human IgG Fc region and the CD2 binding portion of LFA-3; inhibits T-cell activation by binding to CD2 | |
| chimeric human-mouse Ab, recognizes the alpha subunit of IL-2 receptor (CD25); prevents IL-2 mediated T-cell activation and proliferation, depletion of activated T-cells | |
| binding activates complement and cell-mediated cytotoxicity, block lymphocyte function | |
| inhibits calcineurin required for dephosphorylation of NF-ATc, thus inhibiting T-cell activation | |
|